Red, itchy, and scaly skin from atopic dermatitis and eczema can be uncomfortable, confusing, and all too familiar.

Evommune launches mid-stage trials for immune-modulating drugs targeting skin conditions, backed by $115M funding and led by ex-Dermira executives.